Loading…
Loading…
IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.
MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference.
Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.
Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.
Merck (MRK), the pharmaceutical and vaccine heavyweight priced at $151.07, got a blunt warning Thursday: Keytruda's biosimilar countdown is getting louder. Cipl